China Biologic Products has been named to the 2009 list of "200 Best under a Billion" for Asia, a list put together by Forbes Magazine. China Biologic, which develops and markets plasma-based pharmaceutical products, has been growing through M&A transactions in China’s heavily regulated plasma sector. To create its list, Forbes selects listed companies with revenues of under $1 billion, solid growth history and excellent prospects. More details...

Stock Symbol: (OTCBB: CBPO)